Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

K. Abou‐Alfa, Ghassan; Lau, George; Kudo, Masatoshi; L. Chan, Stephen; Kate Kelley, Robin; Furuse, Junji; Sukeepaisarnjaroen, Wattana; Kang, Yoon‐Koo; Van Dao, Tu; N. De Toni, Enrico; Rimassa, Lorenza; В. Бредер, В.; Vasilyev, Alexander; Heurgué, Alexandra; C. Tam, Vincent; Mody, Kabir; Chiradoni Thungappa, Satheesh; Ostapenko, Yuriy; Yau, Thomas; Jobim Azevedo, Sérgio; Varela, Marı́a; Cheng, Ann‐Lii; Qin, Shukui; R. Galle, Peter; Ali, Sajid; Marcovitz, Michelle; Makowsky, Mallory; He, Philip; F. Kurland, John; Negro, Alejandra; Sangro, Bruno

doi:10.1056/evidoa2100070

Public

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Published in NEJM Evidence • Jun 6, 2022

Authors:

Ghassan K. Abou‐Alfa

George Lau

Masatoshi Kudo

Abstract

BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a ...

Subject

Durvalumab

Tremelimumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!